Ionis (NASDAQ: IONS) holder plans 6,179-share sale after PSU grant

Rhea-AI Filing Summary

Ionis Pharmaceuticals has a planned sale of 6,179 shares of its common stock through Morgan Stanley Smith Barney on NASDAQ, with an approximate sale date of 01/30/2026 and an aggregate market value of 512,905.75. These shares were acquired on 01/29/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan and paid as compensation.

The notice also reports that 9,302 common shares of Ionis were sold on 01/16/2026, generating gross proceeds of 703,138.18. The form includes a representation that the seller is not aware of any undisclosed material adverse information about Ionis’ current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	6179	512905.75	161137930	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/29/2026	PSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			6179	01/29/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	Common Stock	01/16/2026	9302	703138.18

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Ionis (IONS) disclose?

The Form 144 discloses a planned sale of 6,179 Ionis common shares through Morgan Stanley Smith Barney on NASDAQ. The shares were recently acquired as performance stock units under the 2011 Equity Incentive Plan and are being sold as compensation-related stock.

How many Ionis (IONS) shares are planned to be sold and on what exchange?

The filing indicates a planned sale of 6,179 shares of Ionis common stock on NASDAQ. Morgan Stanley Smith Barney is listed as the broker, and the sale is targeted around 01/30/2026, based on the approximate sale date disclosed.

What is the aggregate market value of the Ionis (IONS) shares planned for sale?

The 6,179 Ionis common shares covered by the notice have an aggregate market value of 512,905.75. This figure reflects the total market value of the securities proposed to be sold, as reported in the Form 144 filing’s securities information section.

How were the Ionis (IONS) shares in this Form 144 acquired?

The 6,179 shares were acquired on 01/29/2026 as performance stock units granted under Ionis’ 2011 Equity Incentive Plan. The filing labels the nature of payment as compensation, indicating the shares were received as part of an equity-based compensation arrangement.

Does the Ionis (IONS) Form 144 show any recent prior share sales?

Yes. The filing reports that 9,302 Ionis common shares were sold on 01/16/2026, generating gross proceeds of 703,138.18. This disclosure appears in the section listing securities of the issuer sold during the past three months by the same selling account.

What representation does the seller make in the Ionis (IONS) Form 144?

The seller represents that they do not know any material adverse information about Ionis’ current or prospective operations that has not been publicly disclosed. This statement is required as part of the notice covering the proposed sale of the securities.